Navigation Links
Clinical Study: Dietary Supplement SagaPro Reduces Frequent Urination

REYKJAVIK, Iceland, July 6, 2012 /PRNewswire/ --

A recent clinical study on an Icelandic natural product has shown it to be effective against "nocturia" in those with low or diminished bladder capacity. Nocturia is the medical definition of the frequent need to urinate at night. This problem is common among men with prostate enlargement as well as people of all ages with an overactive bladder.


     (Photo: )

     (Photo: )

The product, SagaPro, which is made from the herb "Angelica archangelica", has been produced by SagaMedica in Iceland since 2005 and is very popular among nocturia sufferers. SagaPro has now been clinically studied and a peer-reviewed paper on the study will be published in the Scandinavian Journal of Urology and Nephrology.[1]

Increased nocturnal bladder volume

The study was performed in Iceland by Encode Ltd. and the whole process lasted one year. A total of sixty-nine participants, all of them men with "lower urinary tract symptoms", which includes prostate enlargement, were required to keep a detailed record of their nocturnal restroom trips as well as the volume of urine before and after a period of 8 weeks while they took either SagaPro or a placebo.

Findings showed significant results among different subgroups. In that regard, SagaPro had a pronounced effect on bladder volume and urinary frequency, two factors which affect the duration and quality of sleep.

"The findings were interesting in many ways. For instance, we saw that SagaPro had a significant and positive effect on those who had a low or diminished nocturnal bladder capacity. This knowledge will help us design other studies on SagaPro in the future" says Dr. Steinthor Sigurdsson, Ph.D. and a researcher at SagaMedica.

Not just a prostate product

The study sheds a light on how SagaPro can help those with prostate enlargement which affects a majority of men over 60. As SagaPro affects the bladder it indirectly helps men with prostate enlargement whose main complaint tends to be increased urinary frequency. The presence of a bladder-relaxing flavonoid in SagaPro had previously suggested the product worked through a bladder-related mechanism. Successful use by women and young people with enuresis (bed-wetting) also hinted at this and now the clinical study confirms that SagaPro affects the bladder, thereby helping sufferers of frequent urination.

Helps international marketing

SagaPro is currently marketed in over 200 retail outlets in the US and Canada. Perla Bjork Egilsdottir is SagaMedica's marketing manager: "The positive outcome of the clinical study will no doubt help us in further marketing SagaPro internationally. We expect the results to greatly increase our sales since the brand "SagaPro" has now been clinically verified for both safety and efficacy; not just the product's individual ingredients," she says.

Further studies

The clinical study on SagaPro is preceded by SagaMedica's considerable research on the Angelica herb. This is the 6th peer-reviewed paper the company's research team publishes since it was founded in 2000. The paper is entitled: "A parallel, randomised, double blind, placebo controlled study to investigate the effect of SagaPro on nocturia in men". Authors are the MD's Gudmundur Geirsson and Hrefna Gudmundsdottir and the biochemists Steinthor Sigurdsson, Perla B. Egilsdottir and professor Sigmundur Gudbjarnason.

Previous studies published by the company research team looked at the herb's potential benefits ranging from effects on a neurotransmitter to promote memory health to the potential uses of Angelica in the battle against cancer. Clinical studies on those properties are expected to follow in the future.

More information about SagaPro can be found on the company's website:

1. DOI NUMBER - 10.3109/00365599.2012.695390 [in press]

SOURCE SagaMedica
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Mindray Medical to Present at AACC Clinical Lab Expo 2012
2. Oncos Therapeutics Announces Clinical Advisory Board for its Oncolytic Virus and Cancer Immunotherapy Development Programs
3. Clinical Chemistry Market Report & Forecast (2012 - 2015): Global Analysis
4. Ulthera Launches New Aesthetic Clinical Indication - Treatment of the Decolletage - in Asia
5. Global Clinical Diagnostics Automation Industry
6. Drug Delivery Technologies Show Promise of Improving Clinical Outcomes for Patients at PODD: Partnership Opportunities in Drug Delivery Conference
7. MicroVention Announces First Patient Enrollment In Clinical Trial To Compare Coiling Technologies For Treating Brain Aneurysms
8. PLC Systems Secures Additional Financing For US Clinical Trials And General Working Capital
9. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
10. Abaxis Enters Into Definitive Agreement To Deliver 300 Piccolo Xpress Instruments For A Four-Year Drug Clinical Trial
11. Access Pharmaceuticals Announces Positive Data From MuGard Phase 4 Clinical Trial In Oral Mucositis At MASCC/ISOO 2012 Symposium
Post Your Comments:
(Date:10/12/2015)... Given the intricacy of the anatomy and physiology of ... drug effectively to a specific ocular site. Several barriers have ... include dilution of a drug by tears, clearance of a ... issues with respect to the cornea, sclera and choroid. Approximately ... due to the aforementioned barriers. --> Given ...
(Date:10/12/2015)... and CRANBURY, N.J. , ... Arroyo LLP announces that a securities fraud ... Court for the District of New Jersey.  The complaint ... (NASDAQGM: FOLD) violated the Securities Exchange Act of 1934 ... making materially false and misleading statements about Amicus Therapeutics, ...
(Date:10/12/2015)...  Millions of smokers worldwide have used vaping to ... An April 2015 study released by a ... cigarettes to be up to 95 percent less harmful ... after the technology was first introduced the potentially harmful ... --> --> Palm Beach Vapors, ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... ... Debbie Vereb has been named the organization’s Executive Vice President of Operations, and ... hired to key leadership roles in the company. , Debbie Vereb’s appointment to ...
(Date:10/13/2015)... ... 13, 2015 , ... Curly Hair Solutions® is thrilled to ... an exhibition featuring the newest products and services to hit the market for ... more excited to unveil their recent partnership with Trade Secrets, a leading Canadian ...
(Date:10/13/2015)... , ... October 13, 2015 ... ... LLC presented results from GyencoloGeneTM, the world’s first commercially-available next-generation sequencing laboratory ... FIGO World Congress of Gynecology and Obstetrics in Vancouver, BC, Canada. ...
(Date:10/13/2015)... NY (PRWEB) , ... October 13, 2015 , ... ... her award winning programs Elder Care Doula Training and End of Life ... elderly in a holistic model, physically, spiritually and emotionally. Based on her ...
(Date:10/12/2015)... ... October 13, 2015 , ... Career Step, ... the release of its new Professional Medical Coding and Billing with Applied PCS ... ICD-10-CM and ICD-10-PCS code sets, earn the Certified Professional Coder (CPC) and Certified ...
Breaking Medicine News(10 mins):